Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S is dated May 26, 2026. The document reports on the company's ongoing share repurchase programme and provides an update on treasury share holdings. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries.
Key Financial Metrics and Capital Allocation
The filing focuses on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Share Repurchase Programme: A total programme of up to DKK 15 billion initiated on February 4, 2026, for a 12-month period.
- Recent Activity (May 18–22, 2026): Repurchased 1,050,000 B shares with a total transaction value of approximately DKK 300.8 million.
- Accumulated Repurchases (Since Feb 4, 2026): Total of 17,049,028 B shares repurchased at an average price of DKK 262.22, totaling DKK 4,470,560,295.
- Treasury Shares: The company holds 34,234,329 B shares as treasury shares, representing 0.8% of the total share capital (4,465,000,000 shares).
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the last announcement on March 18, 2026, the company has executed five transactions between May 18 and May 22, 2026. The average purchase price for these recent transactions ranged between DKK 283.90 and DKK 289.34, which is higher than the overall programme average of DKK 262.22.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the remaining balance of the DKK 15 billion programme through February 1, 2027. The specific sub-programme initiated on May 6, 2026, targets up to DKK 11.2 billion.
Risks and Contingencies: The filing does not disclose specific operational risks or contingencies. It notes that transaction details are published on the company website in accordance with EU Market Abuse Regulation (MAR) Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining balance of the DKK 15 billion share repurchase programme.
- Confirm the current market price of Novo Nordisk B shares relative to the recent average buyback price of DKK 287.
- Review the company's full annual or quarterly reports (Form 20-F) for operational financial metrics (revenue, earnings, cash flow) not included in this 6-K.
- Check the company website for the detailed transaction log of the repurchase programme.